Asset profile

Hrain anti-BCMA CAR-T

Cell therapy

Ungradedevidence

Evidence outlook

Completed readouts not yet graded

This drug has completed mid- or late-stage studies whose evidence has not yet been graded on this platform. Where a sponsor has not posted registry results, topline data typically arrives via company announcements — see News.

How the evidence outlook works ↗

Upcoming events

(8 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (2)
December 2026 (2)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2026-12 · NCT06793449 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2026-12-31 · NCT04271644 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (5)
March 2027 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-03 · NCT06880393 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2027 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-07-31 · NCT07489534 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2027 (3)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-08-01 · NCT07106736 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-08-01 · NCT07106684 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-08-01 · NCT07106710 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (1)
February 2028 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2028-02-01 · NCT07477912 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.